Putting Patients First Blog
JUNE 26, 2025
The NHC supports the efforts to reduce out-of-pocket costs for Medicare beneficiaries and appreciates CMS’ work to establish a process that seeks to incorporate patient perspectives into drug pricing policy. The IPAY 2028 guidance introduces a preliminary framework for addressing this evolution through potential renegotiation of MFPs.
Pharmaceutical Technology
JULY 10, 2025
Sectors Sections Clinical Trials Drug Manufacturers Therapy Area Pricing and Market Access Latest E. Keytruda, which brought in $30bn in revenue in 2024, is approaching patent expirations set in 2028, and Merck is therefore intensifying efforts to restructure its portfolio, according to a report by Reuters.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioPharma Dive
JUNE 26, 2025
The company has had a good deal of success with Jakafi, a multipurpose drug approved to treat rare blood cancers and graft-versus-host disease. But Jakafi’s main patents expire in 2028, a date that for years now has been on investors’ radar as they’ve pressed Incyte on what it expects will take the drug’s place. TechTarget, Inc.s
Pharmaceutical Technology
JULY 28, 2025
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? With the data and analytics market in pharmaceuticals now set to be worth $2.1bn by 2028, data needs to be integrated meaningfully to change healthcare outcomes.
Pharmaceutical Technology
JUNE 10, 2025
Go deeper with GlobalData Reports United States of America (USA) Drug Pricing and Reimbursement Lands. Without removing the current members, the current Trump administration would not have been able to appoint a majority of new members until 2028, RFK Jr wrote. Data Insights The gold standard of business intelligence.
Pharmaceutical Technology
SEPTEMBER 15, 2022
According to GlobalData’s report, Paxlovid, the company’s small-molecule Covid-19 oral therapy, was shown to reduce Covid-19 infections by 32% in adults and is forecast to be the top-selling drug by total sales, generating $81bn between 2021 and 2028. AbbVie reported a 22.7% Bristol Myers Squibb (BMS) documented a 9.1%
Big Molecule Watch
NOVEMBER 6, 2023
The licensure and marketing of WEZLANA could affect negotiations with CMS regarding Medicare pricing for STELARA under the Inflation Reduction Act’s Drug Price Negotiation Program. FDA’s approval of WEZLANA has also been raised as a pertinent fact in one of the pending challenges to the Drug Price Negotiation Program.
Expert insights. Personalized for you.
Let's personalize your content